Immunic, Inc. IMUX
7.96 USD +0.21 (+2.71%)
At closeNov 9, 2026, 4:38 PM EST
7.95 -0.01 -0.13%
After hours · Nov 9, 4:38 PM ET
7.55 Day range 8.22
5.06 52-week range 17.43
- YTD
- +49.06%
- 1 year
- +10.71%
News
marketbeat.com Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results Immunic NASDAQ: IMUX is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in progressive disease, with the first patients expected to enroll in the first half…
prnewswire.com Immunic to Participate in Investor Conferences in November NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced…
benzinga.com Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Immunic (NASDAQ:IMUX) with a Overweight rating.
benzinga.com Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new…- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.
benzinga.com Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45 Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.- benzinga.com Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 60 percent increase over losses of $(2.00) per…
benzinga.com Immunic Announces Presentation Of One Late-Breaking And Two Additional Posters Highlighting Additional Data From Its Phase 2 CALLIPER Trial Immunic, Inc.(NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and…
benzinga.com EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates…- benzinga.com B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27 B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.
benzinga.com Immunic Appoints Michael W. Bonney As Board Chairman Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate Immunic (NASDAQ:IMUX) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.68 percent. This is a 332 percent decrease over losses of $(0.25) per…
benzinga.com Amazon To Rally More Than 26%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings
benzinga.com HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22 HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.
benzinga.com Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clinical and regulatory strategy.- benzinga.com Immunic Announces 1-For-10 Reverse Stock Split, Effective April 27 Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will…
benzinga.com Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
benzinga.com Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5 Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.
benzinga.com This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Guggenheim Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $7 Guggenheim analyst Yatin Suneja initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $7.
benzinga.com Twilio To Rally More Than 32%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts changed outlook on top names: BTIG cut CRWD PT, Piper Sandler cut BSY PT, RBC Capital cut AARD PT, TD Cowen raised TWLO PT, Morgan Stanley raised FLYW PT, Stifel boosted QSR PT,…
benzinga.com HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $5 HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $5.- benzinga.com Immunic Q4 EPS $(0.07) Beats $(0.09) Estimate Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 18.6 percent. This is a 72 percent increase over losses of $(0.25) per…
benzinga.com What Does the Market Think About Immunic Inc? 
benzinga.com Why Is Immunic Stock Soaring Friday? Immunic stock surges on oversubscribed private placement raising $400 million to accelerate commercialization.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Immunic Stock Jumps After Pricing $400 Million Private Placement Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.- benzinga.com D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $4 D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $4.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $8 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $8 price target.- benzinga.com Immunic Announced The Presentation Of Additional Data From Its Phase 2 CALLIPER Trial Of Lead Asset, Vidofludimus Calcium (IMU-838), For Progressive Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Forum 2026 Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity.CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Earnings Scheduled For November 14, 2023 Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.- benzinga.com Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
- benzinga.com Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 104% to $5.55 after the company announced it has been selected by the U.S. Department of Defense for a position on the multiple award Indefinite…
- benzinga.com Earnings Scheduled For February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday saw 219 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 167 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 236 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.